The complaint filed against ADMA Biologics, listed on the NASDAQ as ADMA, centers on violations of the Securities Exchange Act of 1934. According to legal filings, the company allegedly misrepresented its financial health by failing to disclose specific related-party transactions. Furthermore, the suit claims the firm engaged in channel stuffing to artificially inflate reported sales activity, rendering public statements throughout the class period materially misleading.
ADMA Biologics Faces Class Action Lawsuit Over Alleged Misconduct
Investors who held ADMA Biologics stock between August 9, 2024, and March 25, 2026, face a critical deadline as a class action lawsuit moves forward. The DJS Law Group is currently organizing plaintiffs to address allegations that the pharmaceutical company misled the market regarding its financial practices and internal transactions.
Shareholders who incurred losses during this period have until August 10, 2026, to contact the DJS Law Group regarding lead plaintiff appointments. While participation in the recovery process does not strictly require this lead role, the firm is encouraging affected investors to come forward to discuss their legal standing. The litigation seeks to address the impact of these undisclosed activities on the company’s market valuation and investor returns.
Comments (0)
No comments yet. Be the first!